A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness

Thrombosis and Haemostasis

Volumn 76, Issue 4, 1996, Pages 529-534

  Bergmann, Jean François ^a,b   Neuhart, Eric ^a  

^a Enoxaparin in Medicine Study Group   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; HEPARIN;

ACUTE DISEASE; AGED; ARTICLE; BED REST; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GERIATRICS; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0029802696     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650617     Document Type: Article

References (43)

1. Planes A, Vochelle N, Mazas F, Zuckman J, Landais A, Pascariello JC, Weill D, Butel J. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60 (3): 407-10.
2. Barsotti J, Gruel Y, Rosset P, Favard L, Dabo B, Andreu J, Delahousse B, Leroy J. Comparative double blind study of two dosage regimens of low molecular weight heparin in elderly patients with femoral neck fracture. J Orthop Trauma 1990; 4 (4): 371-5.
3. Samama M, Bernard P, Bonnardot JP, Combe-Tamzali S, Lanson Y, Tissot E. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis. Br J Surg 1988; 75 (2): 128-31.
4. Leizorovicz A, Haugh MC, Chapuis FR, Samama MM, Boissel JP. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-20.
5. Nurmohamed MT, Rosendaal FR, Büller HR, Dekker E, Hommes DW, Vandenbroucke JP, Briët E. Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340:152-6.
6. Bergmann JF, Segrestaa JM, Caulin C. Prophylaxis against venous thromboembolism. Br Med J 1992; 305: 1156.
7. Clagett GP, Anderson FA, Levine MN, Salzman EW, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; (Suppl 4) 108: 312-34.
8. Gross JS, Neufeld RR, Libow LS, Gerber I, Rodstein M. Autopsy study of the elderly institutionalized patient. Review of 234 autopsies. Arch Intern Med 1988; 148: 173-6.
9. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. Br Med J 1991; 302: 709-11.
10. Kierkegaard A, Norgren L, Olsson CG, Castenfors J, Persson G, Persson S. Incidence of deep vein thrombosis in bedridden non surgical patients. Acta Med Scand 1987; 222: 409-14.
11. Prescott RJ, Jones DRB, Vasilescu C, Henderson JT, Ruckley CV. Smoking and risk factors in deep vein thrombosis. Thromb Haemost 1978; 40: 128-33.
12. Belch JJ, Lowe GDO, Ward AG, Prentice F, Prentice CRM. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scott Med J 1981; 26: 115-7.
13. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10 (7): 448-50.
14. Dahan R, Houlbert D, Caulin C, Cuzin E, Viltart C, Woler J, Segrestaa JM. Prevention of deep vein thrombosis in elderly medical in-patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986; 16: 159-64.
15. Sandercock PAG, Van Den Belt AGM, Lindley RI, Slattery J. Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry 1993; 56: 17-25.
16. Prins MH, Gelsema R, van Heerde LR, den Ottolander GJH. Prophylaxis of deep venous thrombosis with a low molecular weight heparin (Kabi 2165) in stroke patients. Haemostasis 1989; 19: 245-50.
17. Sandset PM, Dahl T, Stiris M, Rostad B, Scheel B, Abildgaard U. A double-blind randomized placebo-controlled trial of low molecular weight heparin once daily to prevent deep-vein thrombosis in acute ischemic stroke. Semin Thromb Hemost 1990; 16 (suppl): 25-33.
18. Turpie AGG, Hirsh J, Jay RM, Andrew M, Hull RD, Levine MN, Carter CJ, Powers PJ, Magnani HN, Gent M. Double-blind randomized trial of ORG 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet 1987; 1: 523-6.
19. Anderson FA, Wheeler B, Goldberg RJ, Hosmer DW, Forcier A. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152: 1660-4.
20. Coon WW. Epidemiology of venous thromboembolism. Ann Surg 1977; 186 (2): 149-64.
21. Hirsh J, Hull RD, Raskob GE. Epidemiology and pathogenesis of venous thrombosis. J Am Coll Cardiol 1986; 8: 104B-13B.
22. Janssen HF, Schachner J, Hubbard J, Hartman JT. The risk of deep venous thrombosis: A computerized epidemiologic approach. Surg 1987; 101 (2): 205-12.
23. Samama MM, Simonneau G, Wainstein JP, de Vathaire F, Huet Y, Landauer D. SIRIUS study: Epidemiology of risk factors of deep venous thrombosis of the lower limbs in community practice. Thromb Haemost 1993; 69 (6): 763 (Abs 797).
24. Gibbs NM. Venous thrombosis of the lower limbs with particular reference to bedrest. Br J Surg 1957; 45: 209.
25. Salzman EW, Hirsh J. Prevention of venous thromboembolism In: Hemostasis and thrombosis: Basic principles and clinical practice. Colman RW, Hirsh J, Marder V, Salzman EW, eds. JB Lippincott Compagny, Philadelphia, PA 1987; 1252-65.
26. Thromboembolic Risk Factors Consensus Group. Risk of and prophylaxis for venous thromboembolism in hospital patients. Br Med J 1992; 305: 567-74.
27. Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79: 1-17.
28. Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Tech M, Gent M, Kelton JG. Heparin induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J 1995; 332: 1330-5.
29. Nicolaides AN. Prevention of venous thromboembolism - European consensus statement. International Angiol 1992; 11, 2: 151-9.
30. Anderson FA, Brownell Wheeler M, Godberg RJ, Hosmer DW, Forcier A, Patwardhan NA. Physician practices in the prevention of venous thromboembolism. Ann Intern Med 1991; 115: 591-5.
31. Anderson FA, Brownell Wheeler M, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991; 151: 933-8.
32. Halkin G, Golberg HJ, Modan M, Modan B. Reduction of mortality in general medical in-patients by low-dose heparin prophylaxis. Ann Intern Med 1982; 96: 5.
33. Noble S, Peters DH, Goa KL. Enoxaparin: a reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease. Drugs 1995; 49(3): 388-410.
34. 125I fibrinogen test. Arch Surg 1972; 104: 152-9.
35. Gillings D, Koch G. The application of the principle of intention-to-treat to the analysis of clinical trials. Drug Information J 1991; 25: 411-24.
36. Com-Noughe C, Rodary C. Revue des procédures statistiques pour mettre en évidence l'équivalence de deux traitements. Rev Epidémiol Santé Publ 1987; 35: 416-30.
37. Deheuvels P. How to analyze bioequivalence studies? The right use of confidence intervals. J Organizational Behav Statist 1984; 1: 1-15.
38. Caulin C. Influence de l'administration de CY 216 sur la mortalité hospitalière des patients alités en médecine interne. Etude coopérative internationale en double-insu, méthodes et résultats préliminaires. In: Fraxiparine. Premier symposium international. Données analytiques, structurales, pharmacologiques et cliniques. Breddin K, Fareed J, Samama M, eds. Stuttgart, New York: Schattauer 1989: 149-54.
39. Harenberg J, Kallenbach B, Martin U, Dempfle CE, Zimmermann R, Kübler W, Heene DL. Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 1990; 59: 639-50.
40. Harenberg J, Roebruck P, Heinrich F, Schmitz-Huebner U, Heene DL. A randomized double blind trial of low molecular weight heparin for prophylaxis of thromboembolism in medical in-patients. Thromb Haemost 1993; 69 (6): 648 (AB 380).
41. Keller F, Flosbach CW and the PRIME study group. A randomized multicentre study investigating the efficacy and safety of the low molecular weight heparin enoxaparin versus unfractionated heparin in the prevention of thromboembolism in immobilized medical patients. Thromb Haemost 1995; 73(6):1106 (Abs 788).
42. Wheeler HB, Hirsh J, Wells P, Anderson FA. Diagnosis tests for deep vein thrombosis. Arch Intern Med 1994; 154: 1921-8.
43. Heijboer H, ten Cate JW, Büller HR. Diagnosis of venous thrombosis. Semin Thromb Hemost 1991; 17 (suppl 3): 259-68.